Otsuka bids for a seat at the conjugate table
The acquisition of Araris follows a 2023 discovery collaboration.
Astra gives in vivo Car-T its biggest endorsement
The company buys Belgium’s EsoBiotec for $425m.
Sutro calls time on folate
At long last luvelta-T is shelved, and Sutro seeks a new focus.
Nuvation sets its sights on Voranigo
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
No lost causes at Xilio and Lyell
The companies press on with vilastobart and IMPT-314... up to a point.
